Evaluation of Topical Rebamipide Versus Topical Betamethasone for Treatment of Oral Aphthous Ulcers
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Treatment of Oral Aphthous Ulcers: A Randomized Clinical Trial
The goal of this randomized clinical trial is to to compare the effect of topical rebamipide to topical betamethasone on pain intensity in patients having recurrent oral aphthous ulcers. The main question it aims to answer is :
What is the effect of topical Rebamipide mouthwash compared to topical betamethasone mouthwash on pain reduction in patients with oral aphthous ulcers?
Participants will will be divided randomly into the two groups and the following outcomes will be measured:
Pain associated with oral ulcers Number of oral ulcers Diameter of oral ulcers Healing time of oral ulcers
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is a Randomized clinical trial (RCT) parallel groups, two arm, equivalence framework with 1:1 allocation ratio which is based on the hypothesis that topical rebamipide has comparable effect to topical betamethasone on pain intensity in patients having recurrent oral aphthous ulcers.
The participants will be recruited from the pool of the Clinics Medicine, Periodontology and Diagnostic centre, Faculty of Dentistry - Cairo University. The eligible participants will be enrolled in the study in a consecutive order till the sample size is achieved.
Simple randomization will be generated using computerized random number generator (random.org) with allocation ratio (1:1).
Allocation concealment will be done using sequentially numbered sealed opaque containers of the same shape, size and colour until interventions are assigned.
The entire procedure will be explained to the patients and a written consent will be obtained by the operator.
Participants and care givers will be blinded as both topical rebamipide and topical betamethasone mouthwashes will be of same consistency and will be provided in sealed opaque containers of the same shape, size and colour.
The enrolled patients will be divided randomly into two groups. One group will receive topical rebamipide mouthwash four times daily for one week or till healing and the other group will receive topical Corticosteroid (topical betamethasone) four times daily for one week or till healing. The patients will be recalled in the first week (days 3, 5 and 7). The patients will be asked to prohibit use of any topical medication during the trial. Outcome measures will be recorded in each visit.
Data will be analyzed using IBM SPSS advanced statistics (Statistical Package for Social Sciences), version 24 (SPSS Inc., Chicago, IL)
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Mostafa Belal, MSc
- Telefonnummer: 01223384483
- E-Mail: mostafa.belal@dentistry.cu.edu.eg
Studieren Sie die Kontaktsicherung
- Name: Sherine Ali, Professor
- Telefonnummer: 01280777749
- E-Mail: Shereen.Ali@dentistry.cu.edu.eg
Studienorte
-
-
-
Cairo, Ägypten
- Rekrutierung
- Faculty of dentistry, Cairo University
-
Kontakt:
- Mostafa Belal, MSc
- Telefonnummer: 01223384483
- E-Mail: mostafa.belal@dentistry.cu.edu.eg
-
Kontakt:
- Sherine Ali, Professor
- Telefonnummer: 01280777749
- E-Mail: Shereen.Ali@dentistry.cu.edu.eg
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria:
Patients age from 18-70 years old. Patients with active oral ulcers. History of recurrent ulcers in the oral cavity Patients free from any visible oral lesions other than the oral aphthous ulcers.
Patient who will agree to participate in the study and take the supplied interventions.
E8glusion criteria:
- Patients with history of a severe or chronic medical condition including congestive heart failure, malignancy and active infection including tuberculosis, hepatitis and human immunodeficiency virus.
- Patients under immunosuppressive drugs.
- Patients using topical or systemic treatment agents for the oral ulcers
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Rebamipide mouthwash
Rebamipide mouthwash will be administered four times daily for one week or till healing |
Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
Andere Namen:
|
|
Aktiver Komparator: Betamethasone mouthwash
Betamethasone mouthwash of will be administered four times daily for one week or till healing |
Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pain intensity associated with oral aphthous ulcers
Zeitfenster: During the first week (days 0, 3,5 and 7)
|
pain from oral ulcers will be assessed through visual analogue scale |
During the first week (days 0, 3,5 and 7)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of oral ulcers
Zeitfenster: During the first week (days 0, 3,5 and 7)
|
Number of oral ulcers will be determined through clinical examination |
During the first week (days 0, 3,5 and 7)
|
|
healing time of oral ulcers
Zeitfenster: During the first week (days 0, 3,5, and 7)
|
healing time of oral ulcers will be determined through clinical examination |
During the first week (days 0, 3,5, and 7)
|
|
Diameter of oral ulcers
Zeitfenster: During the first week (days 0, 3,5 and 7),
|
Diameter of oral ulcers will be determined through clinical examination |
During the first week (days 0, 3,5 and 7),
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Akagi S, Fujiwara T, Nishida M, Okuda A, Nagao Y, Okuda T, Tokuda H, Takayanagi K. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019 Jul 25;5:16. doi: 10.1186/s40780-019-0146-2. eCollection 2019.
- Kudur MH, Hulmani M. Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome. Indian J Dermatol. 2013 Sep;58(5):352-4. doi: 10.4103/0019-5154.117298.
- Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. doi: 10.2165/00126839-200304010-00002.
- Nagai N, Seiriki R, Deguchi S, Otake H, Hiramatsu N, Sasaki H, Yamamoto N. Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis. Pharmaceutics. 2020 Jun 9;12(6):532. doi: 10.3390/pharmaceutics12060532.
- Quijano D, Rodriguez M. [Topical corticosteroids in recurrent aphthous stomatitis. Systematic review]. Acta Otorrinolaringol Esp. 2008 Jun-Jul;59(6):298-307. Spanish.
- Ma Y, Yang M, Sun J, Qu X, Qu Z, Qu W. The effectiveness of lower-level laser therapy on the treatment of minor recurrent aphthous ulcers: a systematic review and meta-analysis. Lasers Med Sci. 2025 Nov 25;40(1):493. doi: 10.1007/s10103-025-04700-8.
- Parra-Moreno FJ, Egido-Moreno S, Schemel-Suarez M, Gonzalez-Navarro B, Estrugo-Devesa A, Lopez-Lopez J. Treatment of recurrent aphtous stomatitis: A systematic review. Med Oral Patol Oral Cir Bucal. 2023 Jan 1;28(1):e87-e98. doi: 10.4317/medoral.25604.
- Rogulj AA, Z Alajbeg I, Brailo V, Skrinjar I, Zuzul I, Vucicevic-Boras V, Alajbeg I. Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. PLoS One. 2021 Apr 8;16(4):e0249862. doi: 10.1371/journal.pone.0249862. eCollection 2021.
- Manfredini M, Guida S, Giovani M, Lippolis N, Spinas E, Farnetani F, Dattola A, Di Matteo E, Pellacani G, Giannetti L. Recurrent Aphthous Stomatitis: Treatment and Management. Dermatol Pract Concept. 2021 Sep 1;11(4):e2021099. doi: 10.5826/dpc.1104a99. eCollection 2021 Sep.
- Alsahaf S, Alkurdi KA, Challacombe SJ, Tappuni AR. Topical betamethasone and systemic colchicine for treatment of recurrent aphthous stomatitis: a randomised clinical trial. BMC Oral Health. 2023 Oct 3;23(1):709. doi: 10.1186/s12903-023-03335-x.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Mundkrankheiten
- Stomatognathe Erkrankungen
- Infektionen
- RNA-Virusinfektionen
- Viruserkrankungen
- Picornaviridae-Infektionen
- Tierkrankheiten
- Mundgeschwür
- Maul-und Klauenseuche
- Polycyclische Verbindungen
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Steroide, fluoriert
- Schwangerschaften
- Betamethason
- Rebamipid
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 3623
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .